Danaher Corporation
- Industry
- Life Science Tools
- Exchange
- US
- Country
- USA
- IPO date
- Jan 5, 1979
- Employees
- 58,000
- Website
- www.danaher.com
Composite valuation range · conservative $115–$140 / fair $140–$180 / optimistic $205–$230. At $196.5, Between the fair and optimistic ranges.
At publication $172 (May 25, 2026)
Data from EODHD, shown in the reporting currency; for reference only, not investment advice.
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
History
Danaher Corporation was incorporated in 1969 and was formerly known as Diversified Mortgage Investors, Inc., changing its name to Danaher Corporation in 1984; its IPO date was January 5, 1979. The company was built largely through acquisitions: its Biotechnology segment was founded on Pall and Cytiva, while its Life Sciences segment expanded via deals including AB Sciex, Molecular Devices, Beckman Coulter, Phenomenex, IDT, Aldevron, and Abcam. The company also completed a Veralto spin-off. In February 2026 it announced the acquisition of Masimo for $180 per share in cash, an enterprise value of about $9.9 billion.
Industry position
Danaher is a healthcare company in diagnostics and research, operating through three segments: Biotechnology, Life Sciences, and Diagnostics. In 2025 segment revenue was about $7.293 billion (Biotechnology), $7.334 billion (Life Sciences), and $9.941 billion (Diagnostics), making Diagnostics the largest, with roughly 82% of sales from recurring revenue and about 58,000 employees. Its brands include Cytiva, Pall, Beckman Coulter, Cepheid, Leica, IDT, Abcam, and Radiometer. Named comparable competitors include Thermo Fisher, Agilent, Waters, and Mettler-Toledo; China contributed about $2.631 billion of 2025 revenue, roughly 10.7% of sales.